Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANDROID 5 vs APALUTAMIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.
Apalutamide is a nonsteroidal antiandrogen that inhibits androgen receptor (AR) nuclear translocation, DNA binding, and transcription of AR target genes. It also decreases AR-mediated tumor cell proliferation and increases apoptosis.
Testosterone replacement therapy for male hypogonadism,Off-label: delayed puberty in males
Metastatic castration-sensitive prostate cancer (m CSPC),Non-metastatic castration-resistant prostate cancer (nm CRPC)
2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.
240 mg orally once daily with or without food.
Terminal elimination half-life is 3.5–5.5 hours; clinical effects may persist for several days due to active metabolites.
Terminal elimination half-life is approximately 3 days (72 hours) for apalutamide and 3–5 days for the active metabolite N-desmethyl-apalutamide. The long half-life supports once-daily dosing and requires approximately 2–3 weeks to reach steady state.
Hepatic via CYP3A4 and CYP2B6; undergoes first-pass metabolism.
Primarily metabolized by CYP2C8 and CYP3A4 to active metabolite N-desmethylapalutamide. Also involves glucuronidation by UGTs.
Primarily renal: ~90% as glucuronide and sulfate conjugates, 6% as unchanged drug; ~5% fecal via bile.
Apalutamide and its active metabolite N-desmethyl-apalutamide are eliminated primarily via hepatic metabolism and subsequent fecal excretion. Approximately 65% of the dose is recovered in feces (as unchanged drug and metabolites) and 24% in urine (primarily as metabolites). Renal excretion of unchanged drug is negligible.
98% bound to sex hormone-binding globulin (SHBG) and albumin.
Apalutamide is highly protein bound (>96%), primarily to albumin and alpha-1-acid glycoprotein. No significant displacement interactions are expected with other highly bound drugs.
Vd approximately 1.0 L/kg; indicates extensive tissue distribution, especially to reproductive organs and bone marrow.
Apparent volume of distribution (Vd/F) is approximately 200 L (2.7 L/kg for a 70 kg adult), indicating extensive distribution into tissues including the prostate and other androgen-responsive organs.
Oral: 15–25% due to first-pass metabolism; buccal or transdermal: higher, but not commercially available for this formulation.
Oral bioavailability is not precisely determined due to lack of an intravenous formulation, but absorption is at least 90% based on mass balance studies. Food does not significantly affect absorption, so it can be taken with or without food.
No specific dose adjustment required based on GFR; caution in severe impairment (Cr Cl <30 m L/min) due to potential fluid retention.
No dose adjustment required for mild to moderate renal impairment (e GFR 30-89 m L/min). For severe renal impairment (e GFR 15-29 m L/min), use with caution; no specific dose recommendation. Not studied in end-stage renal disease (e GFR <15 m L/min) or on hemodialysis.
Contraindicated in Child-Pugh class B and C cirrhosis due to hepatotoxicity risk; in class A, use with caution and monitor liver function.
Mild hepatic impairment (Child-Pugh A): No dose adjustment. Moderate hepatic impairment (Child-Pugh B): Reduce dose to 120 mg once daily. Severe hepatic impairment (Child-Pugh C): Not recommended due to lack of data.
Not recommended for use in children as it may cause premature epiphyseal closure and virilization; limited data.
Safety and efficacy not established; no approved pediatric dosing.
Increased risk of prostatic hyperplasia and carcinoma; use lowest effective dose with regular prostate monitoring.
No specific dose adjustment required; consider comorbidities and potential for increased adverse effects based on renal and hepatic function.
Warning: Prolonged use may cause virilization in women, premature epiphyseal closure, and increased risk of prostatic hypertrophy/carcinoma.
None.
Monitor liver function, lipid profile, and prostate-specific antigen; risk of edema in patients with cardiac disease; avoid use in patients with sleep apnea.
Seizures: Discontinue permanently if seizure occurs during treatment.,Fractures and Falls: Increased risk of bone fractures and falls; assess bone density and manage accordingly.,Cardiovascular Events: Increased risk of hypertension, cardiac ischemia, and heart failure; monitor cardiovascular status.,Hypothyroidism: Monitor thyroid function before and during treatment; replacement therapy may be needed.,Embryo-Fetal Toxicity: Can cause fetal harm; advise males with female partners of reproductive potential to use effective contraception.
Known or suspected prostate cancer; breast cancer in males; hypersensitivity to androgens; pregnancy and lactation.
Pregnancy (can cause fetal harm),Women of reproductive potential (unless using effective contraception)
Avoid grapefruit and grapefruit juice as they may increase drug levels. Limit salt intake to reduce fluid retention. Alcohol may increase risk of liver toxicity.
Avoid grapefruit and grapefruit juice due to potential CYP3A4 interaction. No other specific dietary restrictions; can be taken with or without food.
Pregnancy Category X. ANDROID 5 (oxandrolone) is contraindicated in pregnancy due to teratogenic effects including masculinization of female fetus, clitoral enlargement, and labial fusion. Risk is highest during first trimester but applies throughout gestation.
Apalutamide is contraindicated in pregnancy. Based on its mechanism of androgen receptor inhibition, it may cause fetal harm, including feminization of male fetuses and developmental abnormalities. Adequate animal reproduction studies have not been conducted; however, in rats, fetal malformations were observed at exposures below human clinical exposures. Effective contraception is required for females of reproductive potential during treatment and for 3 months after the last dose.
Excretion into human milk is unknown. Due to potential for androgenic effects in nursing infants, breastfeeding is not recommended. No M/P ratio available.
It is unknown whether apalutamide or its metabolites are excreted in human milk. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 3 months after the last dose. M/P ratio is not available.
Not applicable; contraindicated in pregnancy. No dose adjustment recommendations exist for pregnant patients.
No dosing adjustments have been established for pregnancy. Apalutamide is not indicated for use in pregnant women. Physiological changes in pregnancy may alter pharmacokinetics, but no data are available to guide dose modifications.
Android 5 (methyltestosterone) is an androgenic anabolic steroid used for hypogonadism and delayed puberty. Monitor liver function due to hepatotoxicity. Use with caution in elderly due to increased risk of prostatic hypertrophy and carcinoma. Can cause fluid retention in patients with cardiac, renal, or hepatic disease. Avoid in patients with breast cancer or known or suspected prostate cancer.
Apalutamide is an androgen receptor inhibitor used for non-metastatic castration-resistant prostate cancer (nm CRPC). It is a strong CYP3A4 inducer and moderate CYP2C8 inhibitor, requiring careful management of drug interactions. Monitor thyroid function and blood pressure. Concomitant use with warfarin or other anticoagulants may necessitate increased monitoring due to reduced efficacy. Apalutamide can cause seizures; avoid in patients with history of seizure disorders. Baseline and periodic serum lipid profiles and glucose levels are recommended. Dose reduction in severe hepatic impairment (Child-Pugh C) is suggested.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Report any signs of liver problems: yellowing of skin or eyes, dark urine, severe stomach pain.,Women should report any signs of virilization: hoarseness, acne, menstrual changes, growth of facial hair.,Men should report any breast enlargement, changes in urination, or priapism.,Avoid driving or operating machinery if you experience dizziness or drowsiness.,Do not use if you are pregnant or planning to become pregnant.
Take apalutamide with or without food, at the same time each day.,Do not crush, chew, or split tablets; swallow whole.,Avoid grapefruit and grapefruit juice during treatment.,Report signs of seizure, high blood pressure, or thyroid abnormalities to healthcare provider immediately.,Use effective contraception during treatment and for 3 months after last dose; apalutamide may reduce hormonal contraceptive effectiveness.,Inform all healthcare providers of apalutamide use due to potential drug interactions.,May cause fatigue, dizziness, or hot flashes; avoid driving if affected.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANDROID 5 vs APALUTAMIDE, answered by our medical review team.
ANDROID 5 is a Androgen that works by Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.. APALUTAMIDE is a Androgen Receptor Inhibitor that works by Apalutamide is a nonsteroidal antiandrogen that inhibits androgen receptor (AR) nuclear translocation, DNA binding, and transcription of AR target genes. It also decreases AR-mediated tumor cell proliferation and increases apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANDROID 5 and APALUTAMIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANDROID 5 is: 2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.. The standard adult dose of APALUTAMIDE is: 240 mg orally once daily with or without food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANDROID 5 and APALUTAMIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANDROID 5 is classified as Category C. Pregnancy Category X. ANDROID 5 (oxandrolone) is contraindicated in pregnancy due to teratogenic effects including masculinization of female fetus, clitoral enlargement, and labial. APALUTAMIDE is classified as Category C. Apalutamide is contraindicated in pregnancy. Based on its mechanism of androgen receptor inhibition, it may cause fetal harm, including feminization of male fetuses and development. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.